Current perspectives in the management of hyponatremia

Prevention of CPM

Richard H. Sterns, Stephen Silver, B. K. Kleinschmidt-DeMasters, Amyn Mohammed Rojiani

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Central pontine myelinolysis represents a relatively contemporary neurologic entity in which an imbalance of water relative to alterations in the body's electrolyte levels induces characteristic demyelination in the central part of the basis pontis as well as extrapontine sites. The clinical scenario is typically one of chronic hyponatremia followed by a rapid correction to normonatremic or hypernatremic levels. This seemingly innocuous series of events can result in fatal consequences. Better understanding of the pathophysiology of this disorder provides avenues for clinical management, including use of steroids and organic osmoles, such as myoinositol. More recently, the introduction of a newer class of pharmacologic agents - the vasopressin receptor antagonists, known as vaptans, which induce an excretion of increased amounts of water without altered sodium or potassium excretion - is of particular interest. This review addresses classic approaches to the management of this disorder along with a discussion of newer pharmacologic agents that may become important therapeutic interventions in the clinical management of the osmotic myelinolysis syndrome.

Original languageEnglish (US)
Pages (from-to)1791-1797
Number of pages7
JournalExpert Review of Neurotherapeutics
Volume7
Issue number12
DOIs
StatePublished - Dec 1 2007
Externally publishedYes

Fingerprint

Hyponatremia
Central Pontine Myelinolysis
Water
Demyelinating Diseases
Inositol
Nervous System
Electrolytes
Potassium
Sodium
Steroids
Therapeutics
Antidiuretic Hormone Receptor Antagonists

Keywords

  • Central pontine myelinolysis
  • Hyponatremia
  • Myoinositol
  • Steroids
  • Vaptans
  • Vasopressin receptor antagonists

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Current perspectives in the management of hyponatremia : Prevention of CPM. / Sterns, Richard H.; Silver, Stephen; Kleinschmidt-DeMasters, B. K.; Rojiani, Amyn Mohammed.

In: Expert Review of Neurotherapeutics, Vol. 7, No. 12, 01.12.2007, p. 1791-1797.

Research output: Contribution to journalReview article

Sterns, Richard H. ; Silver, Stephen ; Kleinschmidt-DeMasters, B. K. ; Rojiani, Amyn Mohammed. / Current perspectives in the management of hyponatremia : Prevention of CPM. In: Expert Review of Neurotherapeutics. 2007 ; Vol. 7, No. 12. pp. 1791-1797.
@article{f1d7371dc2154dcabe1c1cd7c9bca8b9,
title = "Current perspectives in the management of hyponatremia: Prevention of CPM",
abstract = "Central pontine myelinolysis represents a relatively contemporary neurologic entity in which an imbalance of water relative to alterations in the body's electrolyte levels induces characteristic demyelination in the central part of the basis pontis as well as extrapontine sites. The clinical scenario is typically one of chronic hyponatremia followed by a rapid correction to normonatremic or hypernatremic levels. This seemingly innocuous series of events can result in fatal consequences. Better understanding of the pathophysiology of this disorder provides avenues for clinical management, including use of steroids and organic osmoles, such as myoinositol. More recently, the introduction of a newer class of pharmacologic agents - the vasopressin receptor antagonists, known as vaptans, which induce an excretion of increased amounts of water without altered sodium or potassium excretion - is of particular interest. This review addresses classic approaches to the management of this disorder along with a discussion of newer pharmacologic agents that may become important therapeutic interventions in the clinical management of the osmotic myelinolysis syndrome.",
keywords = "Central pontine myelinolysis, Hyponatremia, Myoinositol, Steroids, Vaptans, Vasopressin receptor antagonists",
author = "Sterns, {Richard H.} and Stephen Silver and Kleinschmidt-DeMasters, {B. K.} and Rojiani, {Amyn Mohammed}",
year = "2007",
month = "12",
day = "1",
doi = "10.1586/14737175.7.12.1791",
language = "English (US)",
volume = "7",
pages = "1791--1797",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - Current perspectives in the management of hyponatremia

T2 - Prevention of CPM

AU - Sterns, Richard H.

AU - Silver, Stephen

AU - Kleinschmidt-DeMasters, B. K.

AU - Rojiani, Amyn Mohammed

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Central pontine myelinolysis represents a relatively contemporary neurologic entity in which an imbalance of water relative to alterations in the body's electrolyte levels induces characteristic demyelination in the central part of the basis pontis as well as extrapontine sites. The clinical scenario is typically one of chronic hyponatremia followed by a rapid correction to normonatremic or hypernatremic levels. This seemingly innocuous series of events can result in fatal consequences. Better understanding of the pathophysiology of this disorder provides avenues for clinical management, including use of steroids and organic osmoles, such as myoinositol. More recently, the introduction of a newer class of pharmacologic agents - the vasopressin receptor antagonists, known as vaptans, which induce an excretion of increased amounts of water without altered sodium or potassium excretion - is of particular interest. This review addresses classic approaches to the management of this disorder along with a discussion of newer pharmacologic agents that may become important therapeutic interventions in the clinical management of the osmotic myelinolysis syndrome.

AB - Central pontine myelinolysis represents a relatively contemporary neurologic entity in which an imbalance of water relative to alterations in the body's electrolyte levels induces characteristic demyelination in the central part of the basis pontis as well as extrapontine sites. The clinical scenario is typically one of chronic hyponatremia followed by a rapid correction to normonatremic or hypernatremic levels. This seemingly innocuous series of events can result in fatal consequences. Better understanding of the pathophysiology of this disorder provides avenues for clinical management, including use of steroids and organic osmoles, such as myoinositol. More recently, the introduction of a newer class of pharmacologic agents - the vasopressin receptor antagonists, known as vaptans, which induce an excretion of increased amounts of water without altered sodium or potassium excretion - is of particular interest. This review addresses classic approaches to the management of this disorder along with a discussion of newer pharmacologic agents that may become important therapeutic interventions in the clinical management of the osmotic myelinolysis syndrome.

KW - Central pontine myelinolysis

KW - Hyponatremia

KW - Myoinositol

KW - Steroids

KW - Vaptans

KW - Vasopressin receptor antagonists

UR - http://www.scopus.com/inward/record.url?scp=37149005779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37149005779&partnerID=8YFLogxK

U2 - 10.1586/14737175.7.12.1791

DO - 10.1586/14737175.7.12.1791

M3 - Review article

VL - 7

SP - 1791

EP - 1797

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 12

ER -